People
The Medicines Company Names Timney as Chief Executive Officer
12 December 2018 - - US-based biopharmaceutical company The Medicines Company's (NASDAQ: MDCO) board of directors has appointed Mark Timney as the company's new chief executive officer and a member of the board of directors, effective immediately, the company said.

Timney will succeed Clive Meanwell, M.D., Ph.D., who has been appointed by the board to serve as chief innovation officer.

Timney has over 25 years of biopharmaceutical industry experience in multi-national companies.

At Merck and Co (NYSE: MRK), Timney led organisations of increasing importance and size, including president US, president Japan and president of Global Primary Care.

In these roles, Timney launched multiple products, many in the cardiovascular therapeutic area, led large organisations of up to 8,000 employees, and was involved in a number of important strategic transactions.

After leaving Merck, Timney served as the CEO of Purdue Pharmaceuticals and formed a company advising healthcare companies.

Before joining Merck, Timney spent eight years working at numerous multinational pharmaceutical companies, including Zeneca Group, ICI Pharmaceuticals and Roussel Labs.

The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare.

The company's goal is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care. The company is headquartered in Parsippany, New Jersey.
Login
Username:

Password: